Axsome Therapeutics Inc (DE:19X)
FRANKFURT:19X
Holding DE:19X?
Track your performance easily

Axsome Therapeutics (19X) Income Statement

2 Followers

Axsome Therapeutics Income Statement

Last quarter (Q2 2024), Axsome Therapeutics's total revenue was $87.17M, an increase of 86.65% from the same quarter last year. In Q2, Axsome Therapeutics's net income was $-77.19M. See Axsome Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 291.49M$ 270.60M$ 50.04M---
Cost of Revenue
$ 28.26M$ 26.07M$ 5.20M---
Gross Profit
$ 263.23M$ 244.53M$ 44.84M---
Operating Expense
$ 525.17M$ 427.44M$ 221.34M$ 124.71M$ 99.14M$ 67.25M
Operating Income
$ -305.71M$ -231.82M$ -179.80M$ -124.71M$ -99.14M$ -67.25M
Net Non Operating Interest Income Expense
$ -4.90M-----
Other Income Expense
$ 3.84M$ 6.45M$ 7.33M$ 5.70M$ 3.81M$ 1.24M
Pretax Income
$ -309.56M$ -238.28M$ -187.13M$ -130.40M$ -102.95M$ -68.48M
Tax Provision
$ -1.00M$ 960.00K----
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -306.39M$ -239.24M$ -187.13M$ -130.40M$ -102.90M$ -68.35M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 510.40M$ 404.59M$ 223.24M$ 124.71M$ 99.14M$ 67.25M
Net Income From Continuing And Discontinued Operation
$ -308.55M$ -239.24M$ -187.13M$ -130.40M$ -102.90M$ -68.35M
Normalized Income
$ -309.13M$ -188.24M----
Interest Expense
------
EBIT
$ -304.60M$ -231.82M$ -179.80M$ -124.71M$ -100.33M$ -67.12M
EBITDA
$ -296.04M$ -224.99M$ -175.40M$ -124.63M$ -100.26M$ -66.43M
Currency in USD

Axsome Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis